substrateBack to the Top
Does anyone know of a DDI case where an intravenously dosed P-gp or CYP
inhibitor has altered the bioavailability of an orally administered P-gp or CYP
substrate, clinically? I'm specifically looking for an effect on first pass,
not systemic clearance.
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Intravenous P-gp or CYP inhibitor affecting first pass of an Oral P-gp or CYP3A4" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (email@example.com)